Transgene
Designs and develops viral-based immunotherapies.
Launch date
Employees
Market cap
$152m
Enterprise valuation
$136m (Public information from Sep 2024)
Share price
€1.038 TNG.PA
Illkirch Grand Est (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 8.0m | 42.0m | 6.7m | 3.0m | 10.0m | 3.1m | 1.2m |
| % growth | - | 425 % | (84 %) | (55 %) | 235 % | (69 %) | (62 %) |
| EBITDA | (26.0m) | 9.0m | (15.5m) | (14.2m) | (16.5m) | (30.3m) | (20.6m) |
| % EBITDA margin | (325 %) | 21 % | (233 %) | (477 %) | (166 %) | (970 %) | (1736 %) |
| Profit | (32.0m) | 8.0m | (18.8m) | (17.2m) | (19.5m) | (32.8m) | (22.3m) |
| % profit margin | (400 %) | 19 % | (283 %) | (578 %) | (195 %) | (1049 %) | (1886 %) |
| R&D budget | - | - | 17.6m | 27.3m | 32.9m | 32.2m | 29.6m |
| R&D % of revenue | - | - | 264 % | 917 % | 329 % | 1029 % | 2499 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
* | N/A | €14.4m | Post IPO Equity |
€48.7m | Secondary | ||
| N/A | €34.1m | - | |
* | N/A | €14.0m | Post IPO Equity |
| Total Funding | $37.5m | ||
Related Content
Recent News about Transgene
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
